Complementary and alternative medicine use by patients enrolled onto phase I clinical trials

Journal of Clinical Oncology

Volumn 22, Issue 23, 2004, Pages 4758-4763

  Dy, Grace K ^a   Bekele, Lishan ^a   Hanson, Lorelei J ^a   Furth, Alfred ^a   Mandrekar, Sumithra ^a   Sloan, Jeff A ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; ECHINACEA EXTRACT;

ADVANCED CANCER; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENERAL PRACTITIONER; HUMAN; MALE; MANIPULATIVE MEDICINE; PHASE 1 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; TEA; TRADITIONAL MEDICINE; ADULT; AGED; COMPARATIVE STUDY; FOLLOW UP; INCIDENCE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; PARASITOLOGY; PATIENT SATISFACTION; PATIENT SELECTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AGED; CLINICAL TRIALS, PHASE I; COMPLEMENTARY THERAPIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SATISFACTION; PATIENT SELECTION; QUESTIONNAIRES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 16544394282     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.121     Document Type: Article

References (36)

1. Cassileth BR, Lusk EJ, Strouse TB, et al: Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Intern Med 101:105-112, 1984
2. Dy GK, Haluska P, Adjei AA: Novel pharmacological agents in clinical development for solid tumours. Expert Opin Investig Drugs 10: 2059-2088, 2001
3. Small EJ, Frohlich MW, Bok R, et al: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595-3603, 2000
4. Holmes MD, Stampfer MJ, Colditz GA, et al: Dietary factors and the survival of women with breast carcinoma. Cancer 86:826-835, 1999
5. Zhang S, Hunter DJ, Forman MR, et al: Dietary carotenoids and vitamins A, C and E and risk of breast cancer. J Natl Cancer Inst 91:547-556, 1999
6. Taylor PR, Li B, Dawsey SM, et al: Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China-Linxian Nutrition Intervention Trials Study Group. Cancer Res 54: 2029s-2031s, 1994 (suppl 7)
7. Neugut AI, Horvath K, Whelan RL, et al: The effect of calcium and vitamin supplements on the incidence and recurrence of colorectal adenomatous polyps. Cancer 78:723-728, 1996
8. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994
9. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440-446, 1998
10. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 83:777-782, 1998
11. Richardson MA, Sanders T, Palmer JL, et al: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514, 2000
12. Zollman C, Vickers A: ABC of complementary medicine: Users and practitioners of complementary medicine. BMJ 319:836-838, 1999
13. Eisenberg DM, Davis RB, Ettner SL, et al: Trends in alternative medicine use in the United States, 1990-1997. JAMA 280:1569-1575, 1998
14. Eisenberg DM, Kessler RC, Foster C, et al: Unconventional medicine in the United States: Prevalence, costs and patterns of use. N Engl J Med 328:246-252, 1993
15. Boon H, Stewart M, Kennard MA, et al: Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol 18:2515-2521, 2000
16. Paltiel O, Avitzour M, Peretz T, et al: Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439-2448, 2001
17. Burstein HJ, Gelber S, Guadagnoli E, et al: Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340: 1733-1739, 1999
18. Lerner IJ, Kennedy BJ: The prevalence of questionable methods of cancer treatment in the United Sates. CA Cancer J Clin 42:181-191, 1992
19. Markman M: Safety issues in using complementary and alternative medicine. J Clin Oncol 20:39s-41s, 2002 (suppl 18)
20. Zollman C, Vickers A: ABC of complementary medicine: What is complementary medicine? BMJ 319:693-696, 1999
21. Blum JR, Keifer J, Rosenblatt M: Distribution free tests of independence based on the sample distribution function. Ann Math Stat 32: 485-498, 1961
22. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
23. Lee MM, Chang JS, Jacobs B, et al: Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 92:1606-1609, 2002
24. Burstein HJ: Discussing complementary therapies with cancer patients: What should we be talking about? J Clin Oncol 18:2501-2504, 2000
25. Stoner GD, Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 22:169-180, 1995
26. Katiyar SK, Mukhtar H: Tea in chemoprevention of cancer: Epidemiologic and experimental studies. Int J Oncol 8:221-228, 1996
27. Muto S, Fujita K, Yamazaki Y, et al: Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 479:197-206, 2001
28. Williams SN, Shih H, Guenette DK, et al: Comparative studies on the effects of green tea extracts and individual tea catechins on human CYP1A gene expression. Chem Biol Interact 128:211-229, 2000
29. Rushmore TH, Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481-490, 2002
30. Khan SG, Katiyar SK, Agarwal R, et al: Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: Possible role in cancer chemoprevention. Cancer Res 52:4050-4052, 1992
31. Coeugniet EG, Elek E: Immunomodulation with Viscum album and Echiancea purpurea extracts. Onkologie 10:27-33, 1987 (suppl 3)
32. Kemp DE, Franco KN: Possible leukopenia associated with long-term use of echinacea. J Am Board Fam Pract 15:417-419, 2002
33. Budzinski JW, Foster BC, Vandenhoek S, et al: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273-282, 2000
34. Scambia G, Ranelletti FO, Benedetti Panici P, et al: Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anticancer Drugs 1:45-48, 1990
35. Tamayo C, Richardson MA, Diamond S, et al: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 14:1-14, 2000
36. Zhang L, Hung MC: Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12:571-576, 1996